- Home
- NRXS vs PMN Comparison
NRXS vs PMN Comparison
Compare NRXS & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRXS
- PMN
- Stock Information
- Founded
- NRXS 2011
- PMN 2004
- Country
- NRXS United States
- PMN Canada
- Employees
- NRXS N/A
- PMN N/A
- Industry
- NRXS
- PMN Pharmaceuticals and Biotechnology
- Sector
- NRXS
- PMN Health Care
- Exchange
- NRXS Nasdaq
- PMN Nasdaq
- Market Cap
- NRXS 25.8M
- PMN 23.5M
- IPO Year
- NRXS 2023
- PMN N/A
- Fundamental
- Price
- NRXS $2.99
- PMN $0.43
- Analyst Decision
- NRXS Strong Buy
- PMN Strong Buy
- Analyst Count
- NRXS 1
- PMN 3
- Target Price
- NRXS $7.00
- PMN $4.33
- AVG Volume (30 Days)
- NRXS 1.0M
- PMN 840.0K
- Earning Date
- NRXS 11-12-2025
- PMN 11-13-2025
- Dividend Yield
- NRXS N/A
- PMN N/A
- EPS Growth
- NRXS N/A
- PMN N/A
- EPS
- NRXS N/A
- PMN N/A
- Revenue
- NRXS $3,217,531.00
- PMN N/A
- Revenue This Year
- NRXS $62.14
- PMN N/A
- Revenue Next Year
- NRXS $131.87
- PMN N/A
- P/E Ratio
- NRXS N/A
- PMN N/A
- Revenue Growth
- NRXS 41.93
- PMN N/A
- 52 Week Low
- NRXS $1.33
- PMN $0.38
- 52 Week High
- NRXS $6.20
- PMN $1.59
- Technical
- Relative Strength Index (RSI)
- NRXS 45.67
- PMN 44.05
- Support Level
- NRXS $2.94
- PMN $0.43
- Resistance Level
- NRXS $3.96
- PMN $0.48
- Average True Range (ATR)
- NRXS 0.31
- PMN 0.04
- MACD
- NRXS -0.06
- PMN -0.00
- Stochastic Oscillator
- NRXS 12.61
- PMN 16.95
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.